EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
Berlin, Germany and Shanghai, China – 23 October 2023 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a.
- Berlin, Germany and Shanghai, China – 23 October 2023 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a.
- Eckert & Ziegler will serve as the supplier for Ablaze’s clinical trial and research activities utilizing Lutetium-177.
- Ablaze is currently developing several Lutetium-based drug products for targeted radiotherapy (TRT).
- "We are excited to support the development of Ablaze’s innovative radiopharmaceuticals by providing our high-quality Lutetium-177,” stated Jutta Ludwig, Member of the Executive Board of Eckert & Ziegler and responsible for the Asia Business.